These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34602478)

  • 1. Automatic Prediction of Cognitive and Functional Decline Can Significantly Decrease the Number of Subjects Required for Clinical Trials in Early Alzheimer's Disease.
    Shafiee N; Dadar M; Ducharme S; Collins DL;
    J Alzheimers Dis; 2021; 84(3):1071-1078. PubMed ID: 34602478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings.
    Baumeister H; Vogel JW; Insel PS; Kleineidam L; Wolfsgruber S; Stark M; Gellersen HM; Yakupov R; Schmid MC; Lüsebrink F; Brosseron F; Ziegler G; Freiesleben SD; Preis L; Schneider LS; Spruth EJ; Altenstein S; Lohse A; Fliessbach K; Vogt IR; Bartels C; Schott BH; Rostamzadeh A; Glanz W; Incesoy EI; Butryn M; Janowitz D; Rauchmann BS; Kilimann I; Goerss D; Munk MH; Hetzer S; Dechent P; Ewers M; Scheffler K; Wuestefeld A; Strandberg O; van Westen D; Mattsson-Carlgren N; Janelidze S; Stomrud E; Palmqvist S; Spottke A; Laske C; Teipel S; Perneczky R; Buerger K; Schneider A; Priller J; Peters O; Ramirez A; Wiltfang J; Heneka MT; Wagner M; Düzel E; Jessen F; Hansson O; Berron D
    Brain; 2024 Jul; 147(7):2400-2413. PubMed ID: 38654513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease.
    Pettigrew C; Soldan A; Sloane K; Cai Q; Wang J; Wang MC; Moghekar A; Miller MI; Albert M;
    Neuroimage Clin; 2017; 16():439-446. PubMed ID: 28879085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of Cognitive Decline for Enrichment of Alzheimer's Disease Clinical Trials.
    Tam A; Laurent C; Gauthier S; Dansereau C
    J Prev Alzheimers Dis; 2022; 9(3):400-409. PubMed ID: 35841241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlating Cognitive Decline with White Matter Lesion and Brain Atrophy Magnetic Resonance Imaging Measurements in Alzheimer's Disease.
    Bilello M; Doshi J; Nabavizadeh SA; Toledo JB; Erus G; Xie SX; Trojanowski JQ; Han X; Davatzikos C
    J Alzheimers Dis; 2015; 48(4):987-94. PubMed ID: 26402108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease.
    Kimura A; Yoshikura N; Hayashi Y; Inuzuka T
    J Alzheimers Dis; 2018; 61(2):581-588. PubMed ID: 29171996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropsychological Decline Improves Prediction of Dementia Beyond Alzheimer's Disease Biomarker and Mild Cognitive Impairment Diagnoses.
    Nation DA; Ho JK; Dutt S; Han SD; Lai MHC;
    J Alzheimers Dis; 2019; 69(4):1171-1182. PubMed ID: 31104015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.
    Jack CR; Wiste HJ; Vemuri P; Weigand SD; Senjem ML; Zeng G; Bernstein MA; Gunter JL; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS;
    Brain; 2010 Nov; 133(11):3336-48. PubMed ID: 20935035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
    Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining structural brain changes improves the prediction of Alzheimer's disease and mild cognitive impairment.
    Zhang N; Song X; Zhang Y;
    Dement Geriatr Cogn Disord; 2012; 33(5):318-26. PubMed ID: 22759808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microstructural brain changes track cognitive decline in mild cognitive impairment.
    Reas ET; Hagler DJ; White NS; Kuperman JM; Bartsch H; Wierenga CE; Galasko D; Brewer JB; Dale AM; McEvoy LK
    Neuroimage Clin; 2018; 20():883-891. PubMed ID: 30290303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment.
    Selnes P; Aarsland D; Bjørnerud A; Gjerstad L; Wallin A; Hessen E; Reinvang I; Grambaite R; Auning E; Kjærvik VK; Due-Tønnessen P; Stenset V; Fladby T
    J Alzheimers Dis; 2013; 33(3):723-36. PubMed ID: 23186987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
    Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
    Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
    Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI and cognitive scores complement each other to accurately predict Alzheimer's dementia 2 to 7 years before clinical onset.
    Zandifar A; Fonov VS; Ducharme S; Belleville S; Collins DL;
    Neuroimage Clin; 2020; 25():102121. PubMed ID: 31931400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years.
    Albert M; Zhu Y; Moghekar A; Mori S; Miller MI; Soldan A; Pettigrew C; Selnes O; Li S; Wang MC
    Brain; 2018 Mar; 141(3):877-887. PubMed ID: 29365053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.